Health Care

Sarepta Therapeutics Inc (SRPT) Rating Increased to Buy at SunTrust Banks, Inc

Granite Point Capital Management, L.p. augmented its investment by buying 39,850 shares an increase of 170.5% in the quarter. Kaye now owns $2,151,311 of the stock according to the SEC filing.

A number of other research firms have also recently weighed in on SRPT.

Sarepta Therapeutics (NASDAQ:SRPT) traded down 4.07% during mid-day trading on Wednesday, reaching $34.40. About 1.82M shares traded. Finally, Edge Wealth Management LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter valued at about $175,000. As of quarter end Point72 Asset Management, L.p. had acquired 1,222,106 shares growing its position 152.1%. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals. Wells Fargo & Company MN now owns 108,477 shares of the biotechnology company's stock worth $3,657,000 after acquiring an additional 23,767 shares during the last quarter. Voya Investment Management LLC boosted its position in Sarepta Therapeutics by 2,786.1% during the second quarter. Shamim Ruff, SVP, Regulatory Affairs & Qual sold $395,950 worth of shares at a price of $43.33 on July 21st. $24.50's average target is 19.45% above currents $20.51 stock price. Following the sale, the senior vice president now owns 22,793 shares of the company's stock, valued at $934,513. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram purchased 47,058 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. The disclosure for this sale can be found here. They now have $30.97 price target on the biotechnology company's stock, up from their previous price target of $30.00.

Analysts await Donnelley Financial Solutions Inc (NYSE:DFIN) to report earnings on November, 1. Credit Suisse Group set a $64.00 target price on shares of Sarepta Therapeutics and gave the stock a buy rating in a research note on Tuesday, July 18th. Finally, Zacks Investment Research downgraded shares of Sarepta Therapeutics from a buy rating to a hold rating in a report on Monday, July 17th. Amer Century Cos holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 37,652 shares. William Blair maintained the stock with "Buy" rating in Wednesday, August 26 report. Needham & Company LLC reaffirmed a positive rating and set a $81.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, January 12th. The forecast of 13 surveyed investment analysts covering the stock advises investors to Buy stake in the company. The stock has a consensus rating of "Buy" and an average target price of $62.31. The company rocked its 52-Week High of $63.73 and touched its 52-Week Low of $26.26. (SRPT) opened at 46.73 on Thursday. The volume of 1.22 Million shares climbed down over an trading activity of 2.62 Million shares. The firm has a 50-day moving average of $31.26 and a 200 day moving average of $33.41. The company has market cap of $511,133.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, July 19th. The company beat the analyst EPS Estimate with the difference of $0.14. The firm had revenue of $35.01 million during the quarter, compared to analysts' expectations of $22.52 million. The firm's revenue was up 350000.0% compared to the same quarter past year. With an institutional ownership near 40.2%, it carries an earnings per share ratio of 1.28. Sarepta Therapeutics, Inc. (SRPT) average trading volume of 2,577,140 during the past month is 9.2% above its average volume over the past year, indicating that investors have been more active than usual in the stock in recent times. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned "Overweight" rating by Piper Jaffray on Monday, August 24. First Allied Advisory Services has invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of global trademark and copyright legislation.

Sarepta Therapeutics, a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Like this


25 September 2017
1910 new jobs with Volvo expansion in Berkeley Co
The facility will also house Volvo's southern regional sales office as well as a training and research and development center. The XC90 has played an important role in Volvo Cars' sales revival in the United States and around the globe.

25 September 2017
Cleveland Cavaliers 'hopeful' Isaiah Thomas will return by January
While the Eastern Conference champions have been encouraged by Thomas' recovery, they will not rush him back. Thomas will be in position to return by January, the organization said in a statement Monday.

25 September 2017
Violent crime increases for second straight year
The increase was driven by an uptick in several major cities, including Chicago, Baltimore and Las Vegas. Since the early 1990s, as the U.S. population has grown, murders have dropped to about 14,000 a year.

25 September 2017
Gurugram municipal polls: BJP bags 13 seats, independents 21, INLD 1
Minor scuffles, however, did break out at some polling booths, although these were resolved after police p. Though the polling percentage was lower in the early hours as the day progressed the voting was brisk.

25 September 2017
Shares in Anadarko Petroleum Corporation (APC) Purchased by Tiaa Fsb
Riley & Co. (NYSE:PFE) has "Buy" rating given on Wednesday, July 29 by Argus Research. (NYSE:PFE) rating on Monday, May 2. Analysts, on average, seem bullish as they suggest APC is worth $11.65 more, giving a target price of $60.48 a share.

25 September 2017
1st woman graduates Marine infantry officer course today
Since then, four female Marine officers have unsuccessfully attempted to go through the infantry course. The course is a prerequisite for ground intelligence officers and considered one of the hardest.

25 September 2017
CBS releases new Young Sheldon promo ahead of tonight's premiere
Plus, he adds, "I think we dealt with [Amy's] answer in a way that felt the most real and natural to the character", he adds. The previous season ended with Sheldon getting down on one knee asking Amy to be his wife.

25 September 2017
Russian Federation committing 'grave human rights violations' in Crime
She said the transfer of hundreds of prisoners and pre-trial detainees violates global law. The Tatar parliament, the Mejlis, boycotted the referendum on joining Russian Federation .

25 September 2017
Capacit'e Infraprojects soars 60 per cent in market debut
Proceeds from the issue will be used to fund working capital requirement, purchase capital assets and general corporate purposes. Its top clients include Kalpataru , Oberoi Realty, Godrej Properties and Prestige Estates Projects.

25 September 2017
No Home Will be Without Power, Says PM
The Centre said the total purview of the scheme is Rs 16,320 crore, and the government's budgetary assistance is Rs 12,320 crore. The scheme will cover all rural families after electrification of all villages by December end, this year.